{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:12:28Z","timestamp":1764940348580,"version":"3.46.0"},"reference-count":26,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2025.2025.0317","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:52:16Z","timestamp":1762152736000},"source":"Crossref","is-referenced-by-count":0,"title":["All-Cause and Exacerbation-Related Readmissions in Thrombotic Microangiopathy Requiring Plasmapheresis: A Population-Based Cohort Study"],"prefix":"10.4274","author":[{"given":"Alexander R.","family":"Thebert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae X.","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misa","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Qasrawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","unstructured":"1. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, L\u00e4mmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15:312-322.","journal-title":"J Thromb Haemost"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","unstructured":"2. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129:2836-2846.","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","unstructured":"3. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Neph-rol. 2013;33:508-530.","journal-title":"Semin Neph-rol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/JBM.S464365","article-title":"A systematic review of the epidemiology and disease burden of congenital and immune-mediated thrombotic thrombocytopenic purpura","volume":"15","author":"Du","year":"2024","unstructured":"4. Du P, Cristarella T, Goyer C, Moride Y. A systematic review of the epidemiology and disease burden of congenital and immune-mediated thrombotic thrombocytopenic purpura. J Blood Med. 2024;15:363-386.","journal-title":"J Blood Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood-2016-11-743104","article-title":"None of the above: thrombotic microangiopathy beyond TTP and HUS","volume":"129","author":"Masias","year":"2017","unstructured":"5. Masias C, Vasu S, Cataland SR. None of the above: thrombotic microangiopathy beyond TTP and HUS. Blood. 2017;129:2857-2863.","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in pa-tients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","unstructured":"6. Kremer Hovinga JA, Vesely SK, Terrell DR, L\u00e4mmle B, George JN. Survival and relapse in pa-tients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500-1511.","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int Suppl. 2009(Suppl 112):S52-S54.","DOI":"10.1038\/ki.2008.622"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (experience of the Oklahoma TTP-HUS Registry, 1989-2007). Kid-ney Int Suppl. 2009(Suppl 112):S8-S10.","DOI":"10.1038\/ki.2008.609"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","unstructured":"9. Vesely SK, George JN, L\u00e4mmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-68.","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.24339","article-title":"Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: a systematic review","volume":"91","author":"Thejeel","year":"2016","unstructured":"10. Thejeel B, Garg AX, Clark WF, Liu AR, Iansavichus AV, Hildebrand AM. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: a systematic review. Am J Hematol. 2016;91:623-630.","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","unstructured":"11. Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, Kremer Hovinga JA, L\u00e4mmle B, Matsumoto M, Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas MR, Tomiyama Y, Veyradier A, Westwood JP, Scully M. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021;137:1855-1861.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","unstructured":"12. Scully M, Cataland SR, Peyvandi F, Coppo P, Kn\u00f6bl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investiga-tors. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335-346.","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","unstructured":"13. Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Big\u00e9 N, Poullin P, Prov\u00f4t F, Martis N, Presne C, Moranne O, Benainous R, Dossier A, Seguin A, Hi\u00e9 M, Wynckel A, Delmas Y, Au-gusto JF, Perez P, Rieu V, Barbet C, Lhote F, Ulrich M, Rumpler AC, de Witte S, Krummel T, Veyradier A, Benhamou Y. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137:733-742.","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Izquierdo","year":"2022","unstructured":"14. Izquierdo CP, Mingot-Castellano ME, Fuentes AEK, Garc\u00eda-Arroba Peinado J, Cid J, Jimenez MM, Valcarcel D, G\u00f3mez-Segu\u00ed I, de la Rubia J, Martin P, Goterris R, Hern\u00e1ndez L, Tall\u00f3n I, Varea S, Fern\u00e1ndez M, Garc\u00eda-Mu\u00f1oz N, Vara M, Zarzoso MF, Garc\u00eda-Candel F, Paciello ML, Garc\u00eda-Garc\u00eda I, Zalba S, Campuzano V, Gala JM, Est\u00e9vez JV, Jim\u00e9nez GM, L\u00f3pez Lorenzo JL, Arias EG, Freir\u00eda C, Sol\u00e9 M, \u00c1vila Idrovo LF, Hern\u00e1ndez Castellet JC, Cruz N, Lavilla E, P\u00e9rez-Monta\u00f1a A, Atucha JA, Moreno Beltr\u00e1n ME, Moreno Mac\u00edas JR, Salinas R, Del Rio-Garma J. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. Blood Adv. 2022;6:6219-6227.","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","unstructured":"15. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18:2496-2502.","journal-title":"J Thromb Haemost"},{"key":"ref15","unstructured":"16. Healthcare Cost and Utilization Project. NRD Overview. Agency for Healthcare Research and Quality, Rockville, 2025. Available online at https:\/\/hcup-us.ahrq.gov\/nrdoverview.jsp"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/hematolrep14030035","article-title":"COVID-19-associated thrombotic thrombocytopenic purpura: a case report and systematic review","volume":"14","author":"Chaudhary","year":"2022","unstructured":"17. Chaudhary H, Nasir U, Syed K, Labra M, Reggio C, Aziz A, Shah P, Reddy R, Sangha N. COVID-19-associated thrombotic thrombocytopenic purpura: a case report and systematic review. Hematol Rep. 2022;14:253-260.","journal-title":"Hematol Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/jha2.577","article-title":"The perfect storm: thrombotic thrombocytopenic pur-pura (TTP) associated with COVID-19, a clinical case series and review","volume":"3","author":"Melissa","year":"2022","unstructured":"18. Melissa N, Adit S, Junaid H, Sean D. The perfect storm: thrombotic thrombocytopenic pur-pura (TTP) associated with COVID-19, a clinical case series and review. EJHaem. 2022;3:1358-1364.","journal-title":"EJHaem"},{"key":"ref18","unstructured":"19. Healthcare Cost and Utilization Project. Elixhauser Comorbidity Software Refined for ICD-10-CM. Agency for Healthcare Research and Quality, Rockville, 2025. Available online at https:\/\/hcup-us.ahrq.gov\/toolssoftware\/comorbidityicd10\/comorbidity_icd10.jsp"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1053\/j.seminhematol.2003.10.001","article-title":"The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS","volume":"41","author":"George","year":"2004","unstructured":"20. George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004;41:60-67.","journal-title":"Semin Hematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/ajhp\/zxae167","article-title":"Clinical and economic burden of sus-pected thrombotic thrombocytopenic purpura in US hospitals","volume":"81","author":"Xing","year":"2024","unstructured":"21. Xing S, Bullano M, Hale S, Lokhandwala T, Murty S. Clinical and economic burden of sus-pected thrombotic thrombocytopenic purpura in US hospitals. Am J Health Syst Pharm. 2024;81:1278-1287.","journal-title":"Am J Health Syst Pharm"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1055\/s-0039-1679907","article-title":"Clinical and laboratory features of patients with acquired thrombotic thrombocytopenic purpura: fourteen years of the Milan TTP Registry","volume":"119","author":"Mancini","year":"2019","unstructured":"22. Mancini I, Pontiggia S, Palla R, Artoni A, Valsecchi C, Ferrari B, Mikovic D, Peyvandi F; Italian Group of TTP Investigators. Clinical and laboratory features of patients with acquired thrombotic thrombocytopenic purpura: fourteen years of the Milan TTP Registry. Thromb Haemost. 2019;119:695-704.","journal-title":"Thromb Haemost"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","unstructured":"23. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116:4060-4069.","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Bae SH, Kim SH, Bang SM. Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura. Blood Res. 2022;57(Suppl 1):37-43.","DOI":"10.5045\/br.2022.2022005"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s12185-023-03657-0","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023","volume":"118","author":"Matsumoto","year":"2023","unstructured":"25. Matsumoto M, Miyakawa Y, Kokame K, Ueda Y, Wada H, Higasa S, Yagi H, Ogawa Y, Sakai K, Miyata T, Morishita E, Fujimura Y; for TTP Group of Blood Coagulation Abnormalities Re-search Study Team, Research on Rare and Intractable Diseases, Health and Labour Scienc-es Research Grants from the Ministry of Health, Labour and Welfare of Japan. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol. 2023;118:529-546.","journal-title":"Int J Hematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1160\/TH09-08-0595","article-title":"Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population","volume":"103","author":"Wahl","year":"2010","unstructured":"26. Wahl PM, Terrell DR, George JN, Rodgers JK, Uhl L, Cataland S, Bohn RL. Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population. Thromb Haemost. 2010;103:1203-1209.","journal-title":"Thromb Haemost"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:07:46Z","timestamp":1764940066000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-43815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":26,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2025.2025.0317","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"type":"print","value":"1300-7777"},{"type":"electronic","value":"1308-5263"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}